BiotechTube

Selumetinib granule formulation + Selumetinib capsule formulation

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 1

Conditions

Neurofibromatosis Type 1

Trial Timeline

Jan 21, 2022 → Apr 28, 2028

NCT ID
NCT05309668

About Selumetinib granule formulation + Selumetinib capsule formulation

Selumetinib granule formulation + Selumetinib capsule formulation is a phase 1/2 stage product being developed by AstraZeneca for Neurofibromatosis Type 1. The current trial status is active. This product is registered under clinical trial identifier NCT05309668. Target conditions include Neurofibromatosis Type 1.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05309668Phase 1/2Active

Competing Products

20 competing products in Neurofibromatosis Type 1

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60
BinimetinibPacific BiosciencesPhase 2
44

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85